Xtant Medical (XTNT) reported $134M in revenue for fiscal 2025, +14.2% year on year. That ranks #2831 by revenue among 2853 SEC filers and #317 in Healthcare. Net income was $4,973, a net margin of 0.0%. Revenue has grown 11.2% a year on average since 2011 ($30.1M then). The fiscal 2025 balance sheet shows $94.1M in total assets, $17.1M in cash and $11.0M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $134M | +14.2% | FY20252025-12-31 |
| Gross profitGrossProfit | $84.3M | +23.5% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $7.3M | +$19.4M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $4,973 | +$21,422 | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $12.5M | +$24.4M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $2.4M | −42.1% | FY20252025-12-31 |
| Total assetsAssets | $94.1M | +0.3% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $51.0M | +18.6% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $17.1M | +175.1% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $11.0M | −50.0% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $20.9M | −$3.1M | Open → |
| Q2 20262026-06-30 | $23.0M | −$9.4M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Xtant Medical Holdings, Inc.
- Ticker
- XTNT
- Exchange
- NYSE
- SIC classification
- Surgical & Medical Instruments & Apparatus (3841)
- Fiscal year end
- 12-31
- CIK
- 0001453593
Filings
- 10-QAug 11, 2026Open filing →
- 10-QMay 13, 2026Open filing →
- 10-KMar 31, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Beam TherapeuticsBEAM | $140M | −$80.0M |
| NRC HealthNRC | $137M | $11.6M |
| RxsightRXST | $134M | −$38.9M |
| Xtant MedicalXTNT | $134M | $4,973 |
| RidgetechRDGT | $132M | −$1.3M |
| Natural Alternatives InternationalNAII | $130M | −$13.6M |
| Niagen BioscienceNAGE | $129M | $17.4M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Xtant Medical — Key figures |url=https://companiesranked.com/en/company/xtant-medical |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Xtant Medical — Key figures. CompaniesRanked. https://companiesranked.com/en/company/xtant-medicalBibTeX
@misc{companiesranked-en-company-xtant-medical-2026,
author = {{CompaniesRanked}},
title = {{Xtant Medical — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/xtant-medical}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001493152-26-013792 · March 31, 2026
{{cite web |title=Xtant Medical — Key figures — 10-K (0001493152-26-013792) |url=https://www.sec.gov/Archives/edgar/data/1453593/000149315226013792/form10-k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-31}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.